Phreesia (NYSE:PHR – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.03, MarketWatch Earnings reports. Phreesia had a negative net margin of 47.75% and a negative return on equity of 52.47%. The company had revenue of $85.80 million during the quarter, compared to the consensus estimate of $85.26 million. During the same quarter in the prior year, the company posted ($0.89) EPS. The company’s quarterly revenue was up 26.4% compared to the same quarter last year. Phreesia updated its FY 2024 guidance to EPS and its FY 2025 guidance to EPS.
Phreesia Stock Performance
NYSE PHR opened at $23.64 on Friday. Phreesia has a fifty-two week low of $21.96 and a fifty-two week high of $40.00. The business has a 50 day moving average price of $29.53 and a two-hundred day moving average price of $31.35. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.89 and a current ratio of 2.89.
Analyst Ratings Changes
A number of research analysts have recently commented on PHR shares. Citigroup dropped their price objective on shares of Phreesia from $40.00 to $37.00 and set a “buy” rating for the company in a research note on Thursday. Stephens reissued an “overweight” rating and set a $37.00 target price on shares of Phreesia in a research report on Thursday. Canaccord Genuity Group dropped their target price on shares of Phreesia from $46.00 to $43.00 and set a “buy” rating for the company in a research report on Thursday. William Blair reissued an “outperform” rating on shares of Phreesia in a research report on Thursday. Finally, KeyCorp dropped their target price on shares of Phreesia from $45.00 to $40.00 in a research report on Thursday, May 25th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.
Insiders Place Their Bets
In other Phreesia news, SVP Michael J. Davidoff sold 1,075 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $31.75, for a total value of $34,131.25. Following the completion of the transaction, the senior vice president now owns 93,576 shares in the company, valued at approximately $2,971,038. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.80% of the stock is owned by company insiders.
Hedge Funds Weigh In On Phreesia
Institutional investors and hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors grew its position in shares of Phreesia by 154.6% during the second quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock worth $36,000 after buying an additional 866 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Phreesia during the first quarter worth approximately $43,000. State of Wyoming grew its position in shares of Phreesia by 34.6% during the second quarter. State of Wyoming now owns 1,918 shares of the company’s stock worth $59,000 after buying an additional 493 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Phreesia by 85.4% during the third quarter. Tower Research Capital LLC TRC now owns 3,137 shares of the company’s stock worth $80,000 after buying an additional 1,445 shares in the last quarter. Finally, Point72 Hong Kong Ltd grew its position in shares of Phreesia by 266.6% during the first quarter. Point72 Hong Kong Ltd now owns 5,381 shares of the company’s stock worth $142,000 after buying an additional 3,913 shares in the last quarter. 94.37% of the stock is currently owned by hedge funds and other institutional investors.
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
- Five stocks we like better than Phreesia
- Compound Interest and Why It Matters When Investing
- What More Does Chewy Have to Do to Impress Investors?
- Best Restaurant Stocks to Invest in Now
- These 3 Wood Stocks are about to go on Discount
- How to Invest and Trade Chinese Stocks
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.